Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Jianian HuChong SunJiahong LuChongbo ZhaoJie Lin

Published in: Journal of neurology (2021)

Rituximab was effective in the treatment in CIDP patients, especially in anti-IgG4 antibody-positive patients. Randomized clinical trials are needed to determine the effectiveness and safety of rituximab in CIDP patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
clinical trial
oxidative stress
patient reported outcomes
replacement therapy